ADIL:NSD-Adial Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.42

Change

+0.14 (+10.94)%

Market Cap

USD 0.03B

Volume

0.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Adial Pharmaceuticals Inc (ADIL) Stock Analysis:
Based on the Adial Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Adial Pharmaceuticals Inc is not available over the next 12 months. Adial Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adial Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Adial Pharmaceuticals Inc’s stock price was USD 1.42. Adial Pharmaceuticals Inc’s stock price has changed by +9.23% over the past week, -18.86% over the past month and -39.57% over the last year.

About

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical tri ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

USD16.75B N/A N/A

ETFs Containing ADIL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.41% 50% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.41% 50% F 26% F
Trailing 12 Months  
Capital Gain -37.99% 75% C 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.99% 75% C 38% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.47% 56% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.47% 55% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 56.67% 52% F 26% F
Risk Adjusted Return 16.71% 56% F 46% F
Market Capitalization 0.03B 17% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.72 8% F 9% F
Price / Cash Flow Ratio -2.54 51% F 64% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -518.38% 4% F 3% F
Return on Invested Capital -517.30% 2% F 4% F
Return on Assets -170.58% 1% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.18 40% F 25% F
Short Percent 4.04% 57% F 41% F
Beta 0.63 80% B- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector